Infliximab treatment in resistant pyoderma gangrenosum: A case report Dirençli pyoderma gangrenosumda i̇nfliksimab tedavisi: Bir olgu sunumu
Turkiye Fiziksel Tip ve Rehabilitasyon Dergisi, cilt.58, sa.4, ss.332-334, 2012 (SCI-Expanded, Scopus, TRDizin)
- Yayın Türü: Makale / Tam Makale
- Cilt numarası: 58 Sayı: 4
- Basım Tarihi: 2012
- Doi Numarası: 10.4274/tftr.43760
- Dergi Adı: Turkiye Fiziksel Tip ve Rehabilitasyon Dergisi
- Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, TR DİZİN (ULAKBİM)
- Sayfa Sayıları: ss.332-334
- Anahtar Kelimeler: Pyoderma gangrenosum, infliximab, anti-TNF
- Sağlık Bilimleri Üniversitesi Adresli: Hayır
Özet
Pyoderma gangrenosum (PG) is an uncommon neutrophilic dermatosis consisting of nodules and pustules that ulcerate. Pyoderma gangrenosum is associated with autoimmune disorders such as inflammatory bowel disease, spondyloarthritis, and rheumatoid arthritis. In mild disease, therapy consists of local wound care and topical or intralesional corticosteroids. For more severe disease, systemic agents are necessary. Herein, we present the case of a patient with steroid resistant pyederma gangrenosum associated with ulcerative colitis and ankylosing spondylitis who responded well to infliximab, a tumor necrosis factor blocker. Biological agents (anti-TNF) may be alternative treatment options in patients with resistant PG. © Turkish Journal of Physical Medicine and Rehabilitation, Published by Galenos Publishing.